Company VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-16 pm EDT			5-day change	1st Jan Change
4.76 ^USD	-5.37%		-33.70%	-48.86%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Business Summary

Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Number of employees: 39

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Biotherapeutics 100.0 %	0	100.0 %	1	100.0 %	+107.27%

Sales per region

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	1	100.0 %	+107.27%

Managers

Managers	Title	Age	Since
Maurice Zauderer FOU	Founder	78	96-12-31
Elizabeth Evans COO	Chief Operating Officer	52	01-04-30
Ernie Smith CTO	Chief Tech/Sci/R&D Officer	52	01-05-31
John Leonard PRN	Corporate Officer/Principal	77	-

Members of the board

Members of the board	Title	Age	Since
Bala S. Manian BRD	Director/Board Member	78	04-11-30
Albert Friedberg CHM	Chairman	77	96-12-31
Chrystyna Stecyk BRD	Director/Board Member	61	20-05-13
Gerald van Strydonck BRD	Director/Board Member	79	03-02-28
Maurice Zauderer FOU	Founder	78	96-12-31
Barbara Yanni BRD	Director/Board Member	70	15-01-31
Jacob Frieberg BRD	Director/Board Member	67	15-01-31

Shareholders

Name	Equities	%	Valuation
Friedberg Mercantile Group Ltd. /Friedberg Family/ 49.66 %	579,313	49.66 %	4 M $
Maurice Zauderer 12.15 %	141,745	12.15 %	1 M $
Point72 Asset Management LP 9.990 %	116,547	9.990 %	863 613 $
AIGH Capital Management LLC 5.003 %	58,362	5.003 %	432 462 $
Worth Venture Partners LLC 4.005 %	46,720	4.005 %	346 195 $
Vanguard Group, Inc. (Subfiler) 0.2952 %	3,444	0.2952 %	25 520 $
Renaissance Technologies LLC 0.1965 %	2,293	0.1965 %	16 991 $
Albert Friedberg 0.1794 %	2,093	0.1794 %	15 509 $
Telemetry Investments LLC 0.1698 %	1,981	0.1698 %	14 679 $
Jacob Frieberg 0.1433 %	1,672	0.1433 %	12 390 $

Company contact information

Vaccinex, Inc.

1895 Mount Hope Avenue

14620, Rochester

http://www.vaccinex.com

Sector

This company's sector is not yet available